Abstract
The increasing prevalence of SARS-CoV-2 variants has raised concerns regarding possible decreases in vaccine effectiveness. Here, neutralizing antibody titers elicited by mRNA-based and adenoviral vector-based vaccines against variant pseudotyped viruses were measured. BNT162b2 and mRNA-1273-elicited antibodies showed modest neutralization resistance against Beta, Delta, Delta plus and Lambda variants whereas Ad26.COV2.S-elicited antibodies from a significant fraction of vaccinated individuals had less neutralizing titer (IC 50 <50). The data underscore the importance of surveillance for breakthrough infections that result in severe COVID-19 and suggest a potential benefit by second immunization following Ad26.COV2.S to increase protection from current and future variants.
Keywords: Ad26.COV2.S; BNT162b2; Delta; Delta plus; Lambda; Neutralization; SARS-CoV-2 variant; mRNA-1273.
【저자키워드】 neutralization, SARS-CoV-2 variant, Delta, BNT162b2, Ad26.COV2.S, mRNA-1273., Delta plus, Lambda, 【초록키워드】 viruses, SARS-CoV-2, Vaccine, severe COVID-19, antibody, mRNA-1273, neutralization, variant, SARS-CoV-2 variant, immunization, variants, BNT162b2, Prevalence, Ad26.COV2.S, Surveillance, SARS-CoV-2 variants, mRNA, Effectiveness, breakthrough infections, Beta, Breakthrough infection, Antibody titers, Neutralizing antibody titer, Lambda, Neutralizing titer, Adenoviral vector-based vaccine, neutralizing antibody titers, fraction, Ad26, vaccinated individuals, adenoviral vector-based vaccines, COV2.S, vaccinated individual, benefit, decrease, raised, less, elicited, were measured, pseudotyped virus, mRNA-based, 【제목키워드】 SARS-CoV-2, vector,